MedPath

MEDREGEN LLC

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website
https://www.medregenco.com/

Clinical Trials

7

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 2
7 (100.0%)

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Phase 2
Not yet recruiting
Conditions
Amyotrophic Lateral Sclerosis
Lou Gehrig Disease
Motor Neuron Disease
Motor Neuron Atrophy
Interventions
First Posted Date
2024-03-18
Last Posted Date
2024-08-23
Lead Sponsor
MedRegen LLC
Target Recruit Count
10
Registration Number
NCT06315608

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Phase 2
Not yet recruiting
Conditions
Cytokine Storm
Acute Respiratory Distress Syndrome
Respiratory Failure
Respiratory Distress Syndrome
Respiratory Tract Diseases
Interventions
Drug: MRG-001 (High-dose)
Other: Placebo
Drug: MRG-001 (Low-dose)
First Posted Date
2024-03-13
Last Posted Date
2024-08-23
Lead Sponsor
MedRegen LLC
Target Recruit Count
60
Registration Number
NCT06308926

MRG-001 in Patients With Alcoholic Hepatitis

Phase 2
Not yet recruiting
Conditions
Acute Alcoholic Hepatitis
Alcoholic Hepatitis
Interventions
First Posted Date
2024-03-13
Last Posted Date
2024-03-13
Lead Sponsor
MedRegen LLC
Target Recruit Count
32
Registration Number
NCT06307522

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Phase 2
Recruiting
Conditions
Abdominal Wound
Wound of Skin
Interventions
Drug: Saline
First Posted Date
2023-05-06
Last Posted Date
2024-08-09
Lead Sponsor
MedRegen LLC
Target Recruit Count
10
Registration Number
NCT05844527
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Phase 2
Conditions
COVID-19
ARDS, Human
Stem Cells
Regeneration
Interventions
Drug: Placebo
First Posted Date
2020-11-30
Last Posted Date
2022-02-15
Lead Sponsor
MedRegen LLC
Target Recruit Count
40
Registration Number
NCT04646603
Locations
🇺🇸

Johns Hopkins Medicine, Baltimore, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.